About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. The change is effective immediately, according to ...

The Arvinas fair value estimate has shifted from US$14.56 to US$14.88 per share, a small move that still matters if you are tracking valuation updates closely. Street research ties this change to ...

Arvinas is pushing ahead with plans to expand development of its prostate cancer prospect ARV-766 into earlier-line settings. The biotech linked the protein degrader to declines in the PSA biomarker ...

ARV-393 is an investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell ...

NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump ...

Date & Time: Oct. 8, 12:00–1:00 p.m. HST Presentation order: 11 Poster Number: Late Breaker Abstract 22 Additional information including abstracts can be found on the MDS 2025 website. About ARV-102 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...